Credit Suisse Group Boosts AnaptysBio, Inc. (ANAB) Price Target to $85.00
AnaptysBio, Inc. (NASDAQ:ANAB) had its target price raised by Credit Suisse Group from $38.00 to $85.00 in a note issued to investors on Tuesday. Credit Suisse Group’s price target would indicate a potential upside of 20.72% from the stock’s current price.
A number of other equities analysts have also recently commented on the stock. JMP Securities lifted their price objective on shares of AnaptysBio from $45.00 to $82.00 and gave the stock an “outperform” rating in a research note on Tuesday. Zacks Investment Research raised shares of AnaptysBio from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Robert W. Baird started coverage on shares of AnaptysBio in a research note on Monday, July 10th. They issued an “outperform” rating and a $36.00 price objective for the company. Royal Bank Of Canada started coverage on shares of AnaptysBio in a research note on Thursday, September 14th. They issued an “outperform” rating and a $40.00 price objective for the company. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $35.00 price objective on shares of AnaptysBio in a research note on Tuesday, September 12th. Seven equities research analysts have rated the stock with a buy rating, AnaptysBio currently has an average rating of “Buy” and an average price target of $54.43.
AnaptysBio (NASDAQ:ANAB) traded up 101.17% during mid-day trading on Tuesday, reaching $70.41. 5,824,148 shares of the company’s stock traded hands. The firm’s market cap is $1.43 billion. AnaptysBio has a one year low of $15.17 and a one year high of $70.48. The firm’s 50-day moving average price is $34.23 and its 200 day moving average price is $34.23.
TRADEMARK VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/10/credit-suisse-group-boosts-anaptysbio-inc-anab-price-target-to-85-00.html.
In related news, major shareholder Holdings A/S Novo sold 356,300 shares of AnaptysBio stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the completion of the transaction, the insider now directly owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of AnaptysBio stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $24.35, for a total transaction of $901,924.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,133,940 shares of company stock valued at $24,223,316.
Several hedge funds have recently added to or reduced their stakes in ANAB. Bank of America Corp DE purchased a new position in shares of AnaptysBio during the 1st quarter worth about $123,000. DAFNA Capital Management LLC boosted its stake in shares of AnaptysBio by 22.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 1,000 shares during the period. New York State Common Retirement Fund purchased a new position in shares of AnaptysBio during the 2nd quarter worth about $168,000. TIAA CREF Investment Management LLC purchased a new position in shares of AnaptysBio during the 1st quarter worth about $227,000. Finally, Teachers Advisors LLC boosted its stake in shares of AnaptysBio by 23.4% during the 2nd quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 1,807 shares during the period. 71.35% of the stock is owned by hedge funds and other institutional investors.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.